Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Our current portfolio includes three late-stage product candidates, Cimzia (certolizumab pegol), for the treatment of moderate to severe plaque psoriasis, DRM04, for the treatment of hyperhidrosis, or excessive sweating and DRM01, a topical sebum inhibitor for acne.
Menlo Park, US
62 (est)+83%
Dermira was founded in 2011 and is headquartered in Menlo Park, US

Key People at Dermira

Thomas G. Wiggans

Thomas G. Wiggans

Co-Founder & CEO
Kin Chan

Kin Chan

Vice President of Engineering
Janice Drew

Janice Drew

Vice President & Project Management
Eugene A. Bauer

Eugene A. Bauer

Founder & Chief Medical Officer
Hans Hofland

Hans Hofland

Vice President ofResearch
Chris Griffith

Chris Griffith

Founder & Vice President, Corporate Development & Strategy

Dermira Locations

Menlo Park, US

Dermira Metrics

Dermira Summary

Market capitalization

$1.01 B

Closing share price

Dermira's current market capitalization is $1.01 B.

Dermira Financials

Dermira's revenue is $7.3 M in FY, 2015
FY, 2014FY, 2015


$7.3 M

Operating income

$-31.7 M$-79.6 M

Operating expense total

$39 M$86.9 M

Net Income

$-31.9 M$-78.4 M

Operating cash flow

$33.2 M$51.9 M

    Dermira Market Value History

    We estimate that Dermira's current employees are approximately 31% female and 69% male.

    Dermira Company Life

    You may also be interested in